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Global risk assessment of cardiovascular disease  
in resource constrained settings 
Jacob Kariuki1, Eileen M Stuart-Shor1, Libin Zhang1, Annya Volkova1, Jaime Halliday1, Shannon Sayer1, Jessica DeMita1, Darren Golden1, James Muchira2, 
Samuel Kimani3, Faith Maina4; University of Massachusetts1, Boston; Tumutumu Hospital School of Nursing2; University of Nairobi3 , Kijabe Hospital School of 
Nursing4 
• Cardiovascular disease (CVD) is an emerging problem in 
Sub-Saharan Africa. 
• Many current guidelines recommend using global risk 
assessment (GRA) to quantify the risk for developing 
CVD and to guide treatment and policy. 
• Most GRA tools require lipid measures which are not 
readily available in resource-constrained settings. Of the 
3 most published non-laboratory based tools: Gaziano 
and Framingham substitute BMI for cholesterol; WHO 
does not include BMI or cholesterol. 
 
    
 
BACKGROUND 
 
• GRA scores can be generated at the point-of-care using 
simple screening information and paper tools with 
79.24% accuracy. 
• The population screened had a high clustering of CV risk 
factors and high risk GRA scores; and that information 
can be available in real-time to guide clinicians in 
delivering evidence-based  treatment.  
• Gaziano GRS was highly correlated with Non-lab 
Framingham (0.87) but WHO GRS had low correlation 
with Framingham and Gaziano (0.36; 0.33).  [Limitations; 
the survival data used to calculate Framingham GRS is 
based on US population; WHO is based on a hypothetical 
dataset.] 
• At the population level GRA might be helpful to assess 
country-specific CVD risk, to plan risk reduction 
strategies and to guide health services policy in this 
resource-constrained country but the best tool is unclear.  
• Population based cohort studies are needed to validate 
these tools in low income countries. 
 
 
CONCLUSIONS 
 
NON LABORATORY BASED GRA TOOLS 
 
•  A convenience sample of consecutive patients were 
screened/ treated for CV risk factors had risk factors 
measured.  
 
•  US/Kenyan teams used validated protocols for 
physiologic/ behavioral measures at 5 Kenyan 
community health clinics. 
 
•  Gaziano and Framingham covariates (age, gender, 
smoking, diabetes, SBP, BMI, antihypertensive Rx); WHO 
covariates (age, gender, smoking, diabetes, SBP).  
 
•  Gaziano GRS was calculated with paper tool at the 
point-of-care and recalculated by the researchers; 
Framingham and WHO GRS was calculated from the 
dataset by researchers. 
 
•  Clinical data was abstracted and analyzed using Stata©.  
 
• US/Kenyan IRB approval was obtained.  
 
 
METHODS 
Gaziano : Lancet. 2008  (Men and non-diabetic women not shown). WHO Charts: J Hypertens. 2007 (Non-diabetics not included). D'Agostino : Circulation. 2008 (Framingham non-lab interactive 
calculator). 
 
RESULTS 
Pairwise Correlation of the 3 Global Risk Scores (GRS)
FRscore GAZ WHO
FRscore 1.0000
GAZ 0.8652 1.0000
0.0000
WHO 0.3606 0.3332 1.0000
0.0000 0.0000
FRscore =  Non-lab Framingham GRS
GRS = Gaziano non-lab GRS
WHO = WHO non-lab GRS
 
RESULTS 
Key: Global Risk Scores for Framingham & WHO Indicates 10 year risk of developing CVD while 
Gaziano GRA indicates 5 year risk of developing GVD. 
Gaziano: Low <10%; Moderate >=10% to <20%; High >=20% 
Framingham: Low <6%; Moderate >=6% to <20%; High >=20% 
WHO: Low <10%; Moderate >=10% to <30%; High >=30% 
 
 
RESEARCH QUESTIONS/HYPOTHESIS 
Number of Risk Factors 
Composite 
Risk 
n % 
0 Risk Factors 123 22.69 
1 Risk Factor 146 26.94 
2+ Risk 
Factors 
273 50.37 
Key: Composite risk includes age, SBP, BMI, 
smoking, DM, CVD, high chol. 
Gaziano GRA Non-lab 
Framingham 
Non-lab 
WHO 
Absolute Risk n % n % n % 
Low 486 56.32 556 55.88 815 94.55 
Moderate 150 17.38 258 25.90 33 3.83 
High 227 26.30 181 18.20 14 1.62 
Sample Characteristics 
All (N=941) 
n % 
Age 
(mean/SD±) 
48.6 18.70 
Women 734 78.76 
Tribe  
(Kikuyu) 
812 87.88 
Hx HTN 207 26.30 
Anti-HTN Rx 170 18.12 
Hx DM 64 6.89 
Hx Obesity 94 10.28 
Hx High Chol 28 3.03 
Hx CVD 58 6.24 
Current 
Smoking 
55 6.29 
Distribution of Risk Factors by Clinical Cut Points 
Stratified by Gender 
All Men Women 
n % n % n % p value 
Mean Blood Pressure [SBP 137.61, SD 23.61(N=941)] 
SBP ≥ 140 mmHg 383 40.07 88 44.44 290 39.51 0.21 
Mean Blood Glucose [97.53, SD 38.7, (n=935)] 
FBS≥126 or Non 
FBS>200 
39 4.82 8 4.76 31 4.87 0.95 
BMI [24.89, SD 4.92, (n=893)] 
BMI ≥  25 398 44.57 44 23.40 353 50.72 0.00 
BMI ≥ 30 139 15.57 9 4.79 129 18.53 0.00 
SBP = Systolic blood pressure; prehypertension 120-139/90 mmHg; Stage 1= 140-159/90 mmHg; Stage 2 = ≥ 
160/90 mmHg 
RBS = Random blood sugar; glucose intol ≥ 110 mg/dL; Diabetes ≥  126 mg/dL fasting; ≥ 140 mg/dL non-fasting 
BMI = Body mass index; malnourished <18; normal 18-25; overweight 25-29; obese ≥ 30 
